Ivermectin for Covid, The Failure of American Medicine

Ivermectin for Covid, The Failure of American Medicine

The FLCCC Group led by Drs Michael Marek and Dr Pierre Kory have reviewed massive amounts of data from medical studies showing Ivermectin to be highly effective repurposed anti-viral drug. The international study data is massive and overwhelming showing dramatic reduction in mortality from the Covid-19 virus for hospitalized patients (70-90%).  In addition, the data shows excellent prevention of Covid 19 disease when the drug is used for prophylaxis in high risk groups.

The Failure of American Medicine

We now have convincing data showing Ivermectin to be effective drug for prevention and treatment of Covid-19.  As Dr Marek points out in his discussions, the complete disregard for Ivermectin as a preventive drug and effective treatment for Covid -19 by the leadership US government agencies, the CDC, NIH and FDA represents a horrendous failure of American Medicine.

Above Image I-MAsk Proctocol: Kory, Pierre, et al. “Clinical and scientific rationale for the “MATH+” hospital treatment protocol for COVID-19.” Journal of intensive care medicine 36.2 (2021): 135-156.

Header image: Bellevue Hospital Surgeons Get Ready courtesy of NYC Heath Hospitals Bellevue AAMC.


Articles with Related interest

Ivermectin Antiparasitic Anticancer Antiviral WOnder Drug

Jeffrey Dach MD
7450 Griffin Road
Suite 180/190
Davie, Fl 33314



1) Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. (Latest version v1.2 – 6 Jan 2021) January 2021 Project: Ivermectin to prevent and treat COVID-19 Authors: Theresa A Lawrie

2) Dixit, Alok, Ramakant Yadav, and Amit Vikram Singh. “Ivermectin: potential role as repurposed drug for COVID-19.” The Malaysian journal of medical sciences: MJMS 27.4 (2020): 154.

IVM which is a widely used as antiparasitic drug has shown to have antiviral activity in in vitro studies against HIV, dengue, influenza, VEEV and Zika virus. The broad-spectrum antiviral activity of IVM against both RNA and DNA viruses offers an added advantage to its potential use over other antiviral drugs. Studies are available for its use against RNA virus and have also been tested for its effectiveness against SARS-CoV-2 in vitro. Based on evidences it seems prudent to use IVM empirically and conduct well designed controlled randomised trials to prove its efficacy in vivo.

3) Chamie-Quintero, Juan, Jennifer A. Hibberd, and David Scheim. “Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase after ivermectin use restricted.” (2021).

Introduction. On May 8, 2020, Peru’s Ministry of Health approved ivermectin (IVM), a drug of Nobel Prize-honored distinction, for inpatient and outpatient treatment of COVID-19. As IVM treatments proceeded in that nation of 33 million residents, excess deaths decreased 14-fold over four months through December 1, 2020, consistent with clinical benefits of IVM for COVID-19 as have emerged in several RCTs. But after IVM use was sharply restricted under a new president, excess deaths then increased 13-fold.
Methods. To evaluate possible IVM treatment effects suggested by these aggregate trends, excess deaths were analyzed by state for ages ≥ 60 in Peru’s 25 states. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations and seropositivity rates were also examined.
Results. The 25 states of Peru were grouped by extent of IVM distributions: maximal (mass IVM distributions through operation MOT, a broadside effort led by the army); medium (locally managed IVM distributions); and minimal (restrictive policies in one state, Lima). The mean reduction in excess deaths 30 days after peak deaths was 74% for the maximal IVM distribution group, 53% for the medium group and 25% for Lima. Reduction of excess deaths is correlated with extent of IVM distribution by state with p<0.002 using the Kendall τb test.
Conclusion. Mass treatments with IVM, a drug safely used in 3.7 billion doses worldwide since 1987, most likely caused the 14-fold reductions in excess deaths in Peru, prior to their 13-fold increase after IVM policy was reversed. This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

4) Lehrer, Steven, and Peter H. Rheinstein. “Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2.” in vivo 34.5 (2020): 3023-3026.

We used the program AutoDock Vina Extended to perform the docking study. Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08. Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane.

5) Vora, Agam, et al. “White paper on Ivermectin as a potential therapy for COVID-19.” indian journal of tuberculosis 67.3 (2020): 448-451.

“Ivermectin in the dose of 12 mg BD alone or in combination with other therapy for 5 to 7 days may be considered as safe therapeutic option for mild moderate or severe cases of Covid-19 infection. It is cost effective especially when the other drugs are very costly & not easily available”.

6) López-Medina E, et al. “Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021 Mar 4:e213071.

Importance: Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit.

Objective: To determine whether ivermectin is an efficacious treatment for mild COVID-19.

Design, setting, and participants: Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state’s health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020.

Intervention: Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200).

Main outcomes and measures: Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected.

Results: Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group).

Conclusion and relevance: Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.

the relatively young and healthy study population rarely developed complications, rendering the study the ability of ivermectin to prevent the progression of mild COVID-19 to more severe stages would need to be assessed in larger trials.

the study population was relatively young, with few comorbidities and with liver enzyme levels less than 1.5 times the normal level, so the findings may be generalizable only to such populations.

7) Scheim, David, Jennifer A. Hibberd, and Juan Chamie-Quintero. “Protocol violations in López-Medina et al.: switched ivermectin (IVM) and placebo doses, failure of blinding, indicators of over-the-counter IVM use by controls, and blatant conflicts of interest.” (2021).

Given AEs distinctive for IVM use in study controls and failures of blinding and boundaries between IVM and placebo arms, results for study controls are unreliable. Some useful information can nevertheless be salvaged from outcomes for this study’s IVM treatment arm, in which no deaths and generally mild symptoms occurred, with AEs typical for high-dose IVM (replicated in the control group) that were generally mild and transient.

8) Scheim, David. “Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021.” (2021).

9) Podder, Chinmay Saha, et al. “Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study.” IMC Journal of Medical Science 14.2 (2020): 1-8.
Background and objectives: Various existing non-antiviral drugs are being used to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based mostly on existing data from previous coronavirus outbreaks. Ivermectin is one of such agents being widely used to treat early-stage of COVID-19. This study evaluated the outcome of ivermectin treated mild to moderate COVID-19 cases compared to usual care.

Methods: This open-label randomised controlled study was conducted at a sub-district (Upazila) health complex from 1st May 2020 to the end of July 2020. Consecutive RT-PCR positive eligible COVID-19 patients were randomised into control and intervention arms. In the intervention arm, ivermectin 200 micrograms/kg single dose was administered orally in addition to usual care and was followed up till recovery. Repeat RT-PCR was done on day ten since the first positive result. The end point with regard to treatment outcome was time required for the resolution of symptoms from the onset of the symptoms and following enrollement in the study.

Results: A total of 62 mild to moderate COVID-19 patients were enrolled in the study. There were 30 patients in the control arm and 32 patients in the intervention arm. Total recovery time from the onset of symptoms to complete resolution of symptoms of the patients in the intervention arm was 10.09 ± 3.236 days, compared to 11.50 ± 5.32 days in the control arm (95% CI -0.860,3.627, p>. 05) and was not significantly different. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days, which also did not differ significantly from the control arm of 6.33 ± 4.23 days (95% CI – 0.766, 2.808, p> 0.05). Results of negative repeat RT- PCR were not significantly different between control and intervention arms (control 90% vs intervention 95%, p>.05).

Conclusion: Ivermectin had no beneficial effect on the disease course over usual care in mild to moderate COVID-19 cases.


10) Kory, Pierre, et al. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” (2020).

In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by
Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and
clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered
that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory
properties against COVID-19. They then identified repeated, consistent, large magnitude
improvements in clinical outcomes in multiple, large, randomized and observational controlled trials
in both prophylaxis and treatment of COVID-19. Further, data showing impacts on population wide
health outcomes have resulted from multiple, large “natural experiments” that occurred when various

city mayors and regional health ministries within South American countries initiated “ivermectin
distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The
tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of
those regions compared to nearby regions without such campaigns, suggest that ivermectin may
prove to be a global solution to the pandemic. This was further evidenced by the recent incorporation
of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment
guidelines of Belize, Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210
million people. To our knowledge, the current review is the earliest to compile sufficient clinical data
to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in
multiple disease phases. One limitation is that half the controlled trials have been published in peerreviewed
publications, with the remainder taken from manuscripts uploaded to medicine pre-print
servers. Although it is now standard practice for trials data from pre-print servers to immediately
influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a
result of this practice, the FLCCC argues that it is imperative that our major national and
international health care agencies devote the necessary resources to more quickly validate these
studies and confirm the major, positive epidemiological impacts that have been recorded when
ivermectin is widely distributed among populations with a high incidence of COVID-19 infections.


Why aren’t we using Ivermectin? With Dr Tess Lawrie
Why aren’t we using Ivermectin? With Dr Tess Lawrie


Dr. Ryan Cole, CEO and Medical Director of Cole Diagnostics regarding Covid, vaccine, & treatments.
•Mar 26, 2021
Ivermectin Evidence with Dr Tess Lawrie
Published on 12 Mar 2021 / In News and Politics

Ivermectin meta-analysis – the findings – Dr Tess Lawrie
•Premiered Jan 26, 2021

Ngo, Binh T., et al. “The Time to Offer Treatments for COVID-19.” Expert Opinion on Investigational Drugs (2021).
Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. (Latest version v1.2 – 6 Jan 2021)

January 2021  Project: Ivermectin to prevent and treat COVID-19 Authors:Theresa A Lawrie
Chamie-Quintero, Juan J., Jennifer Hibberd, and David Scheim. “Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin treatments.” State-By-State, with Ivermectin Treatments (January 12, 2021) (2021).

These sharp major reductions in COVID-19 mortality following IVM treatment thus occurred in each of Peru’s states, with such especially sharp reductions in close time conjunction with IVM treatments in each of the nine states of operation MOT. Its safety well established even at high doses, IVM is a compelling option for immediate, large scale national deployments as an interim measure and complement to pandemic control through vaccinations.
Vora, Agam, et al. “White paper on Ivermectin as a potential therapy for COVID-19.” indian journal of tuberculosis 67.3 (2020): 448-451.

“Ivermectin in the dose of 12 mg BD alone or in combination with other therapy for 5 to 7 days may be considered as safe therapeutic option for mild moderate or severe cases of Covid-19 infection. It is cost effective especially when the other drugs are very costly & not easily available”.


Given AEs distinctive for IVM use in study controls and failures of blinding and boundaries between IVM and placebo arms, results for study controls are unreliable. Some

FLCCC WEEKLY UPDATE – Dr Eric Osgood talks to Dr. Jackie Stone of Zimbabwe
•Apr 8, 2021 FLCCC Weekly Update April 7, 2021.

In this episode, Dr. Eric Osgood discusses the use of ivermectin in Zimbabwe with Dr. Jackie Stone. Dr. Stone has been leading the way in her country to save as many people as possible by ensuring that ivermectin can be quickly and easily obtained for prophylaxis and early treatment. Plus, she shares her own harrowing journey as a COVID-19 patient herself—having contracted the disease twice.

Scheim, David. “Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion.” Available at SSRN 3636557 (2020).

in several clinical studies, IVM at doses of up to 2,000 µg/kg, ten times that used in the Florida study, were well tolerated. The potential for major dose-response gains is evaluated based upon studies indicating that IVM shields SARS-CoV-2 spike protein and that this spike protein binds to the CD147 transmembrane receptor as well as to ACE2. The abundant distribution of CD147 on red blood cells (RBCs) suggests a hypothesized “catch” and “clump” framework whereby virally-mediated bindings of RBCs to other RBCs, platelets, white blood cells and capillary walls impede blood flow, which in turn may underlie key morbidities of COVID-19. The proposed catch and clump scenario for COVID-19 has a parallel in malaria, for which CD147 is central to the infectious process. The core morbidity of severe malaria is caused by similar clumps and adhesions to endothelium centering around infected RBCs. These underlie the much greater incidence of severe malaria for blood groups A or B vs. O, caused by adhesive RBC membrane trisaccharides associated with blood groups A and B. COVID-19 is likewise much more prevalent for blood groups A or B vs. O. More generally, hemagglutination, the formation of such RBC-pathogen clusters, is common for enveloped viruses. Under this hypothesized framework, a significantly higher rate of capillary flow in younger people could explain a corresponding decreased severity of COIVD-19. This proposed hypothesis and the associated potential for major IVM dose-response gains could be tested, for example, by monitoring blood flow in COVID-19 patients before and after IVM intake using nailfold capillaroscopy.
Hellwig, Martin D., and Anabela Maia. “A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.” International journal of antimicrobial agents 57.1 (2021): 106248.
Here, we show that countries with routine mass drug administration of prophylactic chemotherapy including ivermectin have a significantly lower incidence of COVID-19.
COVID-19 Causes ‘Hyperactivity’ in Blood-Clotting Cells Jun 29, 2020 12:00 AM  Doug Dollemore Senior Science Writer, University of Utah Health
Zaid, Younes, et al. “Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19.” medRxiv (2020).
We document the presence of SARS-CoV-2 RNA in platelets of COVID-19 patients. Exhaustive assessment of cytokines in plasma and in platelets revealed the modulation of platelet-associated cytokine levels in COVID-19, pointing to a direct contribution of platelets to the plasmatic cytokine load. Moreover, we demonstrate that platelets release their alpha- and dense-granule contents and phosphatidylserine-exposing extracellular vesicles. Functionally, platelets were hyperactivated in COVID-19 subjects, with aggregation occurring at suboptimal thrombin concentrations. Furthermore, platelets adhered more efficiently onto collagen-coated surfaces under flow conditions.

Conclusions These data suggest that platelets could participate in the dissemination of SARS-CoV-2 and in the overwhelming thrombo-inflammation observed in COVID-19. Thus, blockade of platelet activation pathways may improve outcomes in this disease.
Arévalo, A. P., et al. “Ivermectin reduces in vivo coronavirus infection in a mouse experimental model.” Scientific Reports 11.1 (2021): 1-12.
In conclusion, ivermectin diminished the MHV viral load and disease in the mice, being a useful model for further understanding this therapy against coronavirus diseases.

Ivermectin, Covid Golden Bullet ? Prof PAUL MARIK in conversation with Solly Kramer & Friends.Feb 9, 2021
Hill, Andrew, et al. “Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection.” (2021).
Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization.
Pandemic Parallax View Dr Pierre Kory Testimony Senate Homeland Security Committee Hearing on Medical Response to COVID-19 Senator Ben Johnson (R-WI), Chairman
December 8, 2020

Mountains for many centers and countries around the world showing the miraculous effectiveness of ivermectin. It basically obliterates transmission of this virus. If you take it you will not get sick.
We have evidence that ivermectin is effective, not only in prophylaxis, in the prevention. If you take it you will not get sick. We just came across a trial last night from Argentina, by the lead investigator of ivermectin in Argentina, Dr Hector Carvallo. They prophylaxed 800 healthcare workers. Not one got sick. In the 400 that they didn’t prophylax with ivermectin, 58% got sick. 237 of those 400 got sick. If you take it you will not get sick. It has immense and potent antiviral activity.

I’m a lung specialist. I’m an ICU specialist. I’ve cared for more dying Covid patients than anyone can imagine. They’re dying because they can’t breath. They can’t breath. They’re on high-level oxygen delivery devices, they’re on non-invasive ventilators and/or they’re sedated and paralyzed and attached to mechanical ventilators that breath for them. And I watch them every day. They die. By the time they get to me in the ICU they’re already dying. They’re almost impossible to recover.

Earlier treatment is key. We need to off-load the hospitals. We are tired. I can’t keep doing this. If you look at my manuscript and if I have to go back to work next week any further deaths are going to be needless deaths and I cannot be traumatized by that. I cannot keep caring for patients when I know that they could have been saved with earlier treatment and that drug that will treat them and prevent the hospitalization is ivermectin.

The amount of evidence to show that ivermectin is life-saving and protective is so immense and the drug is so safe, my colleagues have talked about it. It must be instituted and implemented.

we now have 11 randomized control trials. Every one of those control trials show that in the ivermectin treated group, lives are saved, there’s less need for hospitalization, there’s less transmission, less case counts. It is a fundamentally and powerfully effective therapy against covid-19.
December 8, 2020 Medical Response to COVID-19 The Senate Homeland Security and Governmental Affairs Committee heard from medical professionals who advocate for alternative COVID-19…
YouTube Nuked Two Videos Of A Senate Hearing On COVID-19 Treatments
January 28, 2021 By Jordan Davidson Sen. Ron Johnson said YouTube, which is owned by Google, removed two videos from a Senate hearing about COVID-19 treatments from its platform on Wednesday.
Doctor pleads for review of data on ivermectin as COVID-19 treatment during Senate hearing
By Kelly Hayes December 8, 2020 FOX TV Digital Team

useful information can nevertheless be salvaged from outcomes for this study’s IVM treatment arm, in which no deaths and generally mild symptoms occurred, with AEs typical for high-dose IVM (replicated in the control group) that were generally mild and transient.

Scheim, David. “Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021.” (2021).




Click to access EVMS_Critical_Care_COVID-19_Protocol.pdf

Paul Marik, MD., Chief of Pulmonary and Critical Care Medicine Eastern Virginia Medical School, Norfolk, VA. Paul Marik, MD is one of the top ICU critical care academic doctors in the nation.(1-2) Dr. Marik wrote a Definitive 37 page Guide with 316 references: EVMS Critical Care COVID-19 Management Protocol 10-29-2020. The Paul Marik COVID Management Protocol includes Iver




Click to access A-Timeline-of-Ivermectin-Related-Events-in-the-COVID-19-Pandemic-March-24-2021.pdf

Published on by
Jeffrey Dach MD

The post Ivermectin for Covid, The Failure of American Medicine appeared first on Jeffrey Dach MD.

%d bloggers like this: